{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:48Z","timestamp":1790179668003,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,8,29]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Proton-pump inhibitors (PPIs) may disrupt lysosomal acidification, a pathway implicated in age-related macular degeneration (AMD) pathogenesis. We evaluated whether sustained PPI exposure increased the risk of incident AMD in older adults aged \u226560 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This retrospective observational cohort study included adults aged \u226560 years with sustained PPI exposure, matched 1:1 to unexposed controls on demographics, overall health, healthcare utilisation, cardiometabolic factors. Participants were identified from electronic health records. Sustained PPI exposure was defined as \u22652 years of cumulative use within 3 years of the first prescription. Fine-Gray models treating death as a competing event estimated subdistribution hazard ratios (sHRs) for AMD within 10 years; cause-specific Cox models provided complementary HRs. Analyses included histamine H2-receptor antagonists (H2-antagonists) as a negative exposure control and active comparator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incident AMD occurred in 814\/49 796 PPI exposed participants (1.64%) and 668\/49 796 controls (1.34%) (overall sHR=1.24, 95%\u2009CI 1.12 to 1.38; p&lt;0.001; HR=1.25, 95%\u2009CI 1.13 to 1.38, p&lt;0.001). Proportional sHRs were non-constant; sHRs were 1.09 (95%\u2009CI 0.91 to 1.29) before 2.5 years and 1.33 (95%\u2009CI 1.17 to 1.51)\u2009thereafter. For non-exudative AMD, 640 PPI exposed (1.29%) and 510 unexposed (1.02%) participants developed disease (overall sHR=1.28, 95%\u2009CI 1.14 to 1.44; p&lt;0.001, HR=1.29, 95%\u2009CI 1.14 to 1.44, p&lt;0.001). Among those with non-exudative AMD, 190\/2503 PPI-exposed participants (7.59%) and 179\/2503 controls (7.15%) progressed to exudative AMD (sHR and HR=1.03, 95%\u2009CI 0.84 to 1.26; p=0.802\u2009and p=0.801, respectively). No association was observed between H2-antagonists and AMD (sHR=1.02, 95%\u2009CI 0.88 to 1.19; p=0.784; HR=1.03, 95%\u2009CI 0.88 to 1.20, p=0.729). Results were consistent in the active-comparator analysis (reciprocal overall sHR=1.24, 95%\u2009CI 1.04 to 1.48; p=0.016; HR=1.25, 95%\u2009CI 1.05 to 1.49, p=0.012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sustained PPI exposure was associated with a modestly higher AMD risk, whereas no association was observed with H2-antagonists. The consistency of the active-comparator findings supports the potential specificity of this association and warrants further investigation to determine its clinical implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2026-002935","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:55:15Z","timestamp":1790178915000},"page":"e002935","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-2845","authenticated-orcid":false,"given":"Maria Anna","family":"Bantounou","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Emfietzoglou","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0766-2992","authenticated-orcid":false,"given":"Konstantinos G","family":"Baroutis","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Starr","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan W","family":"Miller","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios G","family":"Vavvas","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092308551055000_11.3.e002935.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"2026092308551055000_11.3.e002935.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00409-7"},{"key":"2026092308551055000_11.3.e002935.3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"The Lancet"},{"key":"2026092308551055000_11.3.e002935.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011504","article-title":"How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"2026092308551055000_11.3.e002935.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.11.035"},{"key":"2026092308551055000_11.3.e002935.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2015.08.018"},{"key":"2026092308551055000_11.3.e002935.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13041-019-0439-2","article-title":"Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc","volume":"12","author":"Koh","year":"2019","journal-title":"Mol Brain"},{"key":"2026092308551055000_11.3.e002935.8","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.453","article-title":"Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration","volume":"8","author":"Golestaneh","year":"2017","journal-title":"Cell Death Dis"},{"key":"2026092308551055000_11.3.e002935.9","first-page":"737","article-title":"Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin","volume":"40","author":"Holz","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026092308551055000_11.3.e002935.10","doi-asserted-by":"publisher","DOI":"10.4161\/auto.27292"},{"key":"2026092308551055000_11.3.e002935.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0774-5"},{"key":"2026092308551055000_11.3.e002935.12","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-44"},{"key":"2026092308551055000_11.3.e002935.13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/pds.5676","article-title":"Trends in use of proton pump inhibitors among adults in the United States from 1999 to 2018","volume":"32","author":"Bergin","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092308551055000_11.3.e002935.14","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70152","article-title":"Proton Pump Inhibitor Use Exceeding the U.S. Food and Drug Administration Approved Treatment Duration for Patients With Peptic Ulcer Disease: A Retrospective Cohort Study","volume":"34","author":"Villars","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092308551055000_11.3.e002935.15","doi-asserted-by":"crossref","DOI":"10.3399\/BJGPO.2024.0059","article-title":"Prescribing practices for proton pump inhibitors among primary care physicians in England: an evaluation","volume":"9","author":"Plehhova","year":"2025","journal-title":"BJGP Open"},{"key":"2026092308551055000_11.3.e002935.16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/medicina61091569","article-title":"Proton Pump Inhibitors (PPIs)\u2014An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing","volume":"61","author":"Andrawes","year":"2025","journal-title":"Medicina (B Aires)"},{"key":"2026092308551055000_11.3.e002935.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026092308551055000_11.3.e002935.18","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2026092308551055000_11.3.e002935.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03534-z"},{"key":"2026092308551055000_11.3.e002935.20","unstructured":"U.S. Bureau of Labor Statistics . Population level - 55 yrs. & over [LNU00024230], retrieved from FRED, Federal Reserve Bank of St. Louis. 2026. Available: https:\/\/fred.stlouisfed.org\/series\/LNU00024230 [Accessed 22 Apr 2026]."},{"key":"2026092308551055000_11.3.e002935.21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/alz.13477","article-title":"Proton pump inhibitors and dementia: A nationwide population\u2010based study","volume":"20","author":"Pourhadi","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"2026092308551055000_11.3.e002935.22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of Proton Pump Inhibitors With Risk of Dementia","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"2026092308551055000_11.3.e002935.23","doi-asserted-by":"crossref","unstructured":"Northuis CA , Bell EJ , Lutsey PL , et al . Cumulative Use of Proton Pump Inhibitors and Risk of Dementia. Neurology 2023;101. doi:10.1212\/WNL.0000000000207747","DOI":"10.1212\/WNL.0000000000207747"},{"key":"2026092308551055000_11.3.e002935.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02478-y","article-title":"Regular proton pump inhibitor use and incident dementia: population-based cohort study","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"2026092308551055000_11.3.e002935.25","doi-asserted-by":"publisher","DOI":"10.37796\/2211-8039.1013"},{"key":"2026092308551055000_11.3.e002935.26","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030327","article-title":"Association between Proton Pump Inhibitor Use and Parkinson\u2019s Disease in a Korean Population","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026092308551055000_11.3.e002935.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1906643116"},{"key":"2026092308551055000_11.3.e002935.28","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1920-10.2010"},{"key":"2026092308551055000_11.3.e002935.29","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2022.2110729"},{"key":"2026092308551055000_11.3.e002935.30","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0289fje"},{"key":"2026092308551055000_11.3.e002935.31","doi-asserted-by":"publisher","DOI":"10.1159\/000090268"},{"key":"2026092308551055000_11.3.e002935.32","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0675"},{"key":"2026092308551055000_11.3.e002935.33","doi-asserted-by":"crossref","unstructured":"Li Y , Wang Y , Kou L , et al . Plasma exosomes impair microglial degradation of \u03b1\u2010synuclein through V\u2010ATPase subunit V1G1. CNS Neurosci Ther 2024;30. doi:10.1111\/cns.14738","DOI":"10.1111\/cns.14738"},{"key":"2026092308551055000_11.3.e002935.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola","year":"2013","journal-title":"PLoS One"},{"key":"2026092308551055000_11.3.e002935.35","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330168"},{"key":"2026092308551055000_11.3.e002935.36","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310376"},{"key":"2026092308551055000_11.3.e002935.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.08.019"},{"key":"2026092308551055000_11.3.e002935.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00681-7","article-title":"Diet and the gut microbiome in patients with Parkinson\u2019s disease","volume":"10","author":"Kwon","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2026092308551055000_11.3.e002935.39","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317431"},{"key":"2026092308551055000_11.3.e002935.40","doi-asserted-by":"crossref","unstructured":"Zhang Y , Wang T , Wan Z , et al . Alterations of the intestinal microbiota in age-related macular degeneration. Front Microbiol 2023;14. doi:10.3389\/fmicb.2023.1069325","DOI":"10.3389\/fmicb.2023.1069325"},{"key":"2026092308551055000_11.3.e002935.41","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900636","article-title":"Effect of Clostridium butyricum against Microglia-Mediated Neuroinflammation in Alzheimer\u2019s Disease via Regulating Gut Microbiota and Metabolites Butyrate","volume":"64","author":"Sun","year":"2020","journal-title":"Mol Nutr Food Res"},{"key":"2026092308551055000_11.3.e002935.42","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.64.12.14","article-title":"The Association of Antibiotic Use and the Odds of a New-Onset ICD Code Diagnosis of Age-Related Macular Degeneration: A Large National Case-Control Study","volume":"64","author":"Moir","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026092308551055000_11.3.e002935.43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ajpath.2023.04.006","article-title":"The Emerging Role of Gut Microbiota in Age-Related Macular Degeneration","volume":"193","author":"Xiao","year":"2023","journal-title":"Am J Pathol"},{"key":"2026092308551055000_11.3.e002935.44","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2026-002935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:55:19Z","timestamp":1790178919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2026-002935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjophth-2026-002935"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2026-002935","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}